| 1. |
Essential drugs concept the answer to rising costs in the West? |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 467,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 2. |
All eyes on latanoprost for open-angle glaucoma |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 467,
2004,
Page 3-4
&NA;,
Preview
|
|
摘要:
Glaucoma is one of the leading causes of preventable blindness worldwide. It has been estimated that around 3 million individuals in the US have open-angle glaucoma, half of whom are unaware they have the disease. Blindness due to glaucoma currently affects approximately 120 000 US individuals, and costs the US government more than $US1.5 billion annually in social security benefits, lost income and healthcare expenditures. The aim of glaucoma treatment is to lower, and then maintain, intraocular pressure (IOP), to halt progression of the disease. Latanoprost ophthalmic solution [Xalatan] is a prostaglandin F2αanalogue which acts locally in the eye to increase drainage of aqueous humor and reduce IOP. It is indicated for use among patients with open-angle glaucoma or ocular hypertension. The economic effects of latanoprost treatment in patients with open-angle glaucoma were evaluated by a number of researchers presenting their work at a poster session at the 7th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) [Hamburg, Germany; October 2004].
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 3. |
Recommendations for management of fibromyalgia |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 467,
2004,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 4. |
Inconsistencies between UK NICE, BHS hypertension guidelines |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 467,
2004,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 5. |
Fondaparinux good value for money in DVT prevention |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 467,
2004,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 6. |
Undertreatment common among elderly in assisted-living setting |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 467,
2004,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 7. |
Staphylococcal infections increase costs among CV device recipients |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 467,
2004,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 8. |
Drugs, lifestyle changes potentially cost saving in type 2 DM |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 467,
2004,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 9. |
Cisplatin plus either paclitaxel or cyclophosphamide benefits QOL |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 467,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 10. |
A 7% rise in retail drug prices is expected in Hungary in 2005, |
| |
PharmacoEconomics & Outcomes News,
Volume &NA;,
Issue 467,
2004,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2004
数据来源: ADIS
|
首页
